Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
3.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Eur J Haematol
; 111(5): 815-823, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574220
4.
Exploring participant perceptions of a virtually supported home exercise program for people with multiple myeloma using a novel eHealth application: a qualitative study.
Support Care Cancer
; 31(5): 298, 2023 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097319
5.
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Br J Cancer
; 126(5): 718-725, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34802051
6.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
Br J Haematol
; 198(1): 93-102, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383886
7.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
8.
The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada.
J Card Fail
; 28(2): 237-246, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34509599
9.
Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study.
Blood
; 135(21): 1833-1846, 2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32160635
10.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
11.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
12.
Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism.
Curr Issues Mol Biol
; 43(1): 313-323, 2021 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34201211
13.
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Br J Haematol
; 193(3): 532-541, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33559897
14.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
15.
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Eur J Haematol
; 107(4): 416-427, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34129703
16.
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Eur J Haematol
; 107(3): 333-342, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053112
17.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Eur J Haematol
; 106(5): 673-681, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539037
18.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Am J Hematol
; 96(5): 552-560, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650179
19.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
20.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235